 |
1 Disease |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- | AMG 208 / Amgen
Journal: The HOTAIR/miR-214/ST6GAL1 crosstalk modulates colorectal cancer procession through mediating sialylated c-Met via JAK2/STAT3 cascade. (Pubmed Central) - Mar 29, 2020
The HOTAIR/miR-214/ST6GAL1 axis commands the CRC malignancy by modifying c-Met with sialylation and activating JAK2/STAT3 pathway. Our study presents novel insights into CRC progression and provided prospective therapeutic target for CRC.
- AMG 208 / Amgen
Biomarker, New P2 trial, Tumor microenvironment, Metastases: AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - Apr 20, 2015
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- ||| AMG 208 / Amgen
Trial completion, Metastases: A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Dec 17, 2014
P1, N=54, Completed, Sponsor: Amgen
Our study presents novel insights into CRC progression and provided prospective therapeutic target for CRC. Active, not recruiting --> Completed
- || AMG 208 / Amgen
Enrollment change, Metastases: A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 26, 2012
P1, N=54, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed N=102 --> 54
- || AMG 208 / Amgen
Enrollment closed, Metastases: A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Nov 26, 2012
P1, N=54, Active, not recruiting, Sponsor: Amgen
N=102 --> 54 Recruiting --> Active, not recruiting